EBMT 2024 | Is alloSCT a suitable treatment option for older patients with aplastic anemia?

Antonio Risitano • 16 Apr 2024

EBMT 2024

Race

Antonio Risitano, MD, PhD, AORN San Giuseppe Moscati Di Avellino, Avellino, Italy, discusses the role of allogeneic stem cell transplantation (alloSCT) in treating older patients with aplastic anemia. Despite advancements in alloSCT and immunosuppressive treatment improving survival outcomes to 90%, there are still questions about whether alloSCT is suitable for older patients. For patients over 40, matched sibling and unrelated donors achieve favorable outcomes, while mismatched and haploidentical transplants are not as effective. Dr Risitano also addresses graft-versus-host disease (GvHD) and infectious complications of alloSCT. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.